Tenofovir disoproxil fumarate for patients with chronic hepatitis B who have previously failed lamivudine and adefovir

被引：0
|
作者：
Patterson, S. J. [1 ]
George, J. [2 ]
Strasser, S. I. [3 ]
Lee, A. U. [4 ]
Sievert, W. [5 ]
Nicoll, A. J. [6 ]
Desmonad, P. V. [7 ]
Roberts, S. K. [8 ]
Locarnini, S. [9 ]
Bowden, S. [9 ]
Angus, P. W. [1 ]
机构：
[1] Austin Hlth, Melbourne, Vic, Australia
[2] Westmead Hosp, Westmead, NSW, Australia
[3] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[4] Concord Repatriat Gen Hosp, Sydney, NSW, Australia
[5] Monash Med Ctr, Clayton, Vic, Australia
[6] Royal Melbourne Hosp, Melbourne, Vic, Australia
[7] St Vincents Hosp, Melbourne, Vic, Australia
[8] Alfred Hosp, Melbourne, Vic, Australia
[9] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2009年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A302 / A302
页数：1
相关论文
共 50 条
  • [21] COMPARATIVE SAFETY OF TENOFOVIR DISOPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS
    Yu, N. Y.
    Chang, K. C.
    VALUE IN HEALTH, 2020, 23 : S532 - S532
  • [22] Tenofovir disoproxil fumarate for patients with chronic hepatitis B who suboptimal response to non-tenofovir disoproxil fumarate nucleos(t)ide analogs therapy
    Chen, Kwei-Ming
    Chang, Chi-Hsien
    Lee, Jyong-Hong
    Yang, Chi-Chieh
    ADVANCES IN DIGESTIVE MEDICINE, 2020, 7 (04) : 207 - 213
  • [23] Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed
    Ristig, MB
    Crippin, J
    Aberg, JA
    Powderly, WG
    Lisker-Melman, M
    Kessels, L
    Tebas, P
    JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (12): : 1844 - 1847
  • [24] The Conundrum of Lamivudine and Tenofovir Disoproxil Fumarate for Hepatitis B: Fetus Versus Infant
    Rosenthal, Philip
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (02) : 279 - 280
  • [25] Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
    Benhamou, Y
    Tubiana, R
    Thibault, V
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (02): : 177 - 178
  • [26] A randomized trial evaluating the antiviral efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant chronic hepatitis B patients with undetectable hepatitis B virus DNA
    Lee, Heon Ju
    Kim, SangJin
    Kweon, Young-Oh
    Park, Soo Young
    Heo, Jeong
    Woo, Hyun Young
    Hwang, Jaeseok
    Chung, Woo Jin
    Lee, Chang-Hyeong
    Kim, Byung Seok
    Suh, Jeong Ill
    Tak, Won Young
    Jang, Byoung Kuk
    HEPATOLOGY, 2016, 64 : 926A - 927A
  • [27] Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
    Cui, Guangying
    Xu, Xuejun
    Diao, Hongyan
    SCIENTIFIC REPORTS, 2015, 5
  • [28] Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection
    Wai-Kay Seto
    Man-Fung Yuen
    James Fung
    Ching-Lung Lai
    Hepatology International, 2013, 7 : 327 - 334
  • [29] Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
    Guangying Cui
    Xuejun Xu
    Hongyan Diao
    Scientific Reports, 5
  • [30] No Resistance to Tenofovir Disoproxil Fumarate Through 96 Weeks of Treatment in Patients With Lamivudine-Resistant Chronic Hepatitis B
    Corsa, Amoreena C.
    Liu, Yang
    Flaherty, John F.
    Ben Mitchell
    Fung, Scott K.
    Gane, Edward
    Miller, Michael D.
    Kitrinos, Kathryn M.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (12) : 2106 - U393
12345